Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
EvaluatePharma
Evaluate Omnium
Japan Drug Forecasts
European Drug Forecasts
Epi Analyzer
Evaluate Custom Solutions
Evaluate Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Evaluate Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Stallergenes
May 21, 2018
After 11 long years Allergy sees a glimmer of hope
April 11, 2016
Interview – Allergy Therapeutics sniffs out second chance
April 02, 2014
And the winner is Stallergenes... for now
March 18, 2014
Circassia emerges as one of the UK’s most valuable life science companies
December 13, 2013
Stallergenes and ALK-Abelló take a step closer to the US market
December 10, 2013
EP Vantage interview – Stallergenes poised to take first US steps
March 08, 2012
Hay fever vaccines entering new season of innovation
March 05, 2012
Event – Meda hoping for summer success with hay fever drug
October 29, 2010
New majority investor for Stallergenes could spell good news
October 22, 2010
EP Vantage Interview - Stallergenes sets huge goal for US market
April 21, 2010
Positive US data for Stallergenes raise hopes of partnering deal
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
December 10, 2020
Evaluate Vantage 2021 Preview
July 29, 2020
Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020
Editor's Picks
January 18, 2021
Aducanumab tops 2021’s biggest potential launches
January 19, 2021
The pandemic releases its grip on clinical trials
January 21, 2021
2020 drug approvals rise despite Covid-19
January 20, 2021
Glaxo joins the Covid-19 delay queue
January 21, 2021
Merck KGaA’s dual immuno-oncology weapon misfires
